Background: Chimeric antigen receptors (CARs)-engineered T cells (CAR-T cells) therapy is a promising immunotherapy for leukemia. Encouraged by the world's first adult patient who underwent the clinical trial of CAR-T cells therapy achieved great success, more and more institutions and pharmaceutical companies devoted to the CAR-T R&D. This study aimed at exploring the status and trends of current researches on CAR-T cell therapy through bibliometric analysis. Methods: Original publications on CAR-T cell therapy were collected from the Web of Science Core Collection between 2007 and 2019.11.14. Data were analyzed in terms of publication outputs, journals, countries, institutions, authors, co-authorship, co-citation, research hotspots and evolution trends through VOSviewer and CiteSpace. Results: A total of 961 publications were identified in the period of 2007 to 2019. Molecular Therapy published the highest number of publications, followed by followed by Blood, Clinical Cancer Research and Cancer Immunology Research. The USA, which devoted the largest number of articles and the most extensive cooperation with other countries, was the most leading country in this field. The University of Pennsylvania published the largest number of articles were the most influential institution. June CH was the most productive authors in this field. Maude SL had the most cited article published on New Engl J Med in 2014. The hotspots of CAR-T cell therapy research were “CAR”, “immunotherapy”, “lymphocyte”, “antitumor activity” and “leukemia, whereas the major frontier was chronic lymphocytic leukemia. Conclusion: This study gives investigators the landscape of CAR-T cell therapy research from the perspective of bibliometrics.
| Published in | Biomedical Sciences (Volume 6, Issue 4) |
| DOI | 10.11648/j.bs.20200604.16 |
| Page(s) | 111-119 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2020. Published by Science Publishing Group |
CAR-T, Immunotherapy, Bibliometric Analysis, VOSviewer, CiteSpace
| [1] | F. Bray, J. Ferlay, I. Soerjomataram et al., "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA Cancer J Clin, vol. 68, no. 6, pp. 394-424, 2018. |
| [2] | M. Greaves, "Leukaemia 'firsts' in cancer research and treatment," Nature Reviews Cancer, vol. 16, no. 3, pp. 163-172, 2016. |
| [3] | C. Saygin and H. E. Carraway, "Emerging therapies for acute myeloid leukemia," Journal of Hematology & Oncology, vol. 10, no. 1, pp. 93, 2017. |
| [4] | C. N. Simone, J. C. Morris, D. M. Stewart et al., "Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma," Blood, vol. 120, no. 9, pp. 1816-1819, 2012. |
| [5] | B. J. Druker, "Perspectives on the development of imatinib and the future of cancer research," Nature Medicine, vol. 15, no. 10, pp. 1149-1152, 2009. |
| [6] | Z. Y. Wang and Z. Chen, "Acute promyelocytic leukemia: from highly fatal to highly curable," Blood, vol. 111, no. 5, pp. 2505-2515, 2008. |
| [7] | J. J. Cornelissen and D. Blaise, "Hematopoietic stem cell transplantation for patients with AML in first complete remission," Blood, vol. 127, no. 1, pp. 62-70, 2016. |
| [8] | D. O. Acheampong, C. K. Adokoh, D. B. Asante et al., "Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy," Biomedicine & Pharmacotherapy, vol. 97, pp. 225-232, 2018. |
| [9] | R. A. Gardner, O. Finney, C. Annesley et al., "Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults," Blood, vol. 129, no. 25, pp. 3322-3331, 2017. |
| [10] | Z. Wang, Z. Wu, Y. Liu, W. Han, "New development in CAR-T cell therapy," Journal of Hematology & Oncology, vol. 10, no. 1, pp. 53, 2017. |
| [11] | J. N. Kochenderfer, M. E. Dudley, R. O. Carpenter et al., "Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation," Blood, vol. 122, no. 25, pp. 4129-4139, 2013. |
| [12] | B. Cai, M. Guo, Y. Wang et al., "Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia," Journal of Hematology & Oncology, vol. 9, no. 1, pp. 131, 2016. |
| [13] | W. Y. Zhang, Y. Wang, Y. L. Guo et al., "Treatment of CD20-directed chimeric antigen receptor-modified t cells in patients with relapsed or refractory B-cell non-hodgkin lymphoma: an early phase IIa trial report," Signal Transduct Target Ther, vol. 1, pp. 16002, 2016. |
| [14] | C. M. Wang, Z. Q. Wu, Y. Wang et al., "Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial," Clinical Cancer Research, vol. 23, no. 5, pp. 1156-1166, 2017. |
| [15] | J. Pan, Q. Niu, B. Deng et al., "CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia," Leukemia, vol. 33, no. 12, pp. 2854-2866, 2019. |
| [16] | R. A. Morgan, J. C. Yang, M. Kitano et al., "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2," Molecular Therapy, vol. 18, no. 4, pp. 843-851, 2010. |
| [17] | G. Gross, T. Waks, Z. Eshhar, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity," Proc Natl Acad Sci U S A, vol. 86, no. 24, pp. 10024-10028, 1989. |
| [18] | D. L. Porter, B. L. Levine, M. Kalos et al., "Chimeric antigen receptor- modified T cells in chronic lymphoid leukemia," N Engl J Med, vol. 365, no. 8, pp. 725-733, 2011. |
| [19] | V. Prasad, "Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers," Nature Reviews Clinical Oncology, vol. 15, no. 1, pp. 11-12, 2018. |
| [20] | H. Small, "Co-citation in the scientific literature: a new measure of the relationship between two documents," J Am Soc Inf Sci, vol. 24, pp. 265-269, 1973. |
| [21] | H. Liao, M. Tang, L. Luo, C. Li, F. Chiclana, X. Zeng, "A Bibliometric Analysis and Visualization of Medical Big Data Research," Sustainability, vol. 10, no. 2, pp. 166, 2018. |
| [22] | S. L. Maude, N. Frey, P. A. Shaw et al., "Chimeric antigen receptor t cells for sustained remissions in leukemia," N Engl J Med, vol. 371, no. 16, pp. 1507-1517, 2014. |
| [23] | C. Chen, "CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature," J Am Soc Inf Sci Technol, vol. 57, no. 3, pp. 359-377, 2006. |
| [24] | Y. Hong, Q. Yao, Y. Yang et al., "Knowledge structure and theme trends analysis on general practitioner research: a co-word perspective," BMC Family Practice, vol. 17, pp. 10, 2016. |
| [25] | S. S. Neelapu, F. L. Locke, N. L. Bartlett et al., "Axicabtagene ciloleucel CAR T- cell therapy in refractory large B- cell lymphoma," N Engl J Med, vol. 377, no. 26, pp. 2531-2544, 2017. |
| [26] | S. Yang, J. Li, R. P. Gale, X. Huang, "The mystery of chronic lymphocytic leukemia (CLL): why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology," Blood Reviews, vol. 29, no. 3, pp. 205-213, 2015. |
| [27] | Z. Jiang, X. Jiang, S. Chen et al., "Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma," Frontiers in Immunology, vol. 7, pp. 690, 2016. |
| [28] | X. Yao, S. Zhu, J. Huang et al., "Developing a novel anti-bcma CAR-T for relapsed or refractory multiple myeloma," Blood, vol. 134, no. supplement_1, pp. 50, 2019. |
| [29] | U. Anurathapan, A. M. Leen, M. K. Brenner, J. F. Vera, "Engineered T cells for cancer treatment," Cytotherapy, vol. 16, no. 6, pp. 713-733, 2014. |
| [30] | K. Newick, S. O'Brien, E. Moon, S. M. Albelda, "CAR T cell therapy for solid tumors," Annual Review of Medicine, vol. 68, no. 1, pp. 139-152, 2017. |
APA Style
Wei Li, Li Wan. (2020). Bibliometric Analysis of Original Articles on CAR-T Cell Therapy. Biomedical Sciences, 6(4), 111-119. https://doi.org/10.11648/j.bs.20200604.16
ACS Style
Wei Li; Li Wan. Bibliometric Analysis of Original Articles on CAR-T Cell Therapy. Biomed. Sci. 2020, 6(4), 111-119. doi: 10.11648/j.bs.20200604.16
AMA Style
Wei Li, Li Wan. Bibliometric Analysis of Original Articles on CAR-T Cell Therapy. Biomed Sci. 2020;6(4):111-119. doi: 10.11648/j.bs.20200604.16
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.bs.20200604.16,
author = {Wei Li and Li Wan},
title = {Bibliometric Analysis of Original Articles on CAR-T Cell Therapy},
journal = {Biomedical Sciences},
volume = {6},
number = {4},
pages = {111-119},
doi = {10.11648/j.bs.20200604.16},
url = {https://doi.org/10.11648/j.bs.20200604.16},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bs.20200604.16},
abstract = {Background: Chimeric antigen receptors (CARs)-engineered T cells (CAR-T cells) therapy is a promising immunotherapy for leukemia. Encouraged by the world's first adult patient who underwent the clinical trial of CAR-T cells therapy achieved great success, more and more institutions and pharmaceutical companies devoted to the CAR-T R&D. This study aimed at exploring the status and trends of current researches on CAR-T cell therapy through bibliometric analysis. Methods: Original publications on CAR-T cell therapy were collected from the Web of Science Core Collection between 2007 and 2019.11.14. Data were analyzed in terms of publication outputs, journals, countries, institutions, authors, co-authorship, co-citation, research hotspots and evolution trends through VOSviewer and CiteSpace. Results: A total of 961 publications were identified in the period of 2007 to 2019. Molecular Therapy published the highest number of publications, followed by followed by Blood, Clinical Cancer Research and Cancer Immunology Research. The USA, which devoted the largest number of articles and the most extensive cooperation with other countries, was the most leading country in this field. The University of Pennsylvania published the largest number of articles were the most influential institution. June CH was the most productive authors in this field. Maude SL had the most cited article published on New Engl J Med in 2014. The hotspots of CAR-T cell therapy research were “CAR”, “immunotherapy”, “lymphocyte”, “antitumor activity” and “leukemia, whereas the major frontier was chronic lymphocytic leukemia. Conclusion: This study gives investigators the landscape of CAR-T cell therapy research from the perspective of bibliometrics.},
year = {2020}
}
TY - JOUR T1 - Bibliometric Analysis of Original Articles on CAR-T Cell Therapy AU - Wei Li AU - Li Wan Y1 - 2020/12/22 PY - 2020 N1 - https://doi.org/10.11648/j.bs.20200604.16 DO - 10.11648/j.bs.20200604.16 T2 - Biomedical Sciences JF - Biomedical Sciences JO - Biomedical Sciences SP - 111 EP - 119 PB - Science Publishing Group SN - 2575-3932 UR - https://doi.org/10.11648/j.bs.20200604.16 AB - Background: Chimeric antigen receptors (CARs)-engineered T cells (CAR-T cells) therapy is a promising immunotherapy for leukemia. Encouraged by the world's first adult patient who underwent the clinical trial of CAR-T cells therapy achieved great success, more and more institutions and pharmaceutical companies devoted to the CAR-T R&D. This study aimed at exploring the status and trends of current researches on CAR-T cell therapy through bibliometric analysis. Methods: Original publications on CAR-T cell therapy were collected from the Web of Science Core Collection between 2007 and 2019.11.14. Data were analyzed in terms of publication outputs, journals, countries, institutions, authors, co-authorship, co-citation, research hotspots and evolution trends through VOSviewer and CiteSpace. Results: A total of 961 publications were identified in the period of 2007 to 2019. Molecular Therapy published the highest number of publications, followed by followed by Blood, Clinical Cancer Research and Cancer Immunology Research. The USA, which devoted the largest number of articles and the most extensive cooperation with other countries, was the most leading country in this field. The University of Pennsylvania published the largest number of articles were the most influential institution. June CH was the most productive authors in this field. Maude SL had the most cited article published on New Engl J Med in 2014. The hotspots of CAR-T cell therapy research were “CAR”, “immunotherapy”, “lymphocyte”, “antitumor activity” and “leukemia, whereas the major frontier was chronic lymphocytic leukemia. Conclusion: This study gives investigators the landscape of CAR-T cell therapy research from the perspective of bibliometrics. VL - 6 IS - 4 ER -
Information
Email: